Navigation Links
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Date:5/20/2009

June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University's Stern Graduate School of Business.

The terms of Mr. Bentsur's employment are being finalized and will be set forth in an employment agreement with the Company. As an inducement to his employment, the Company has granted Mr. Bentsur options to purchase 600,000 shares of Company common stock, at an exercise price equal to the fair market value of the stock as of May 20, 2009, the date of grant. The options will vest in equal annual installments over a four-year period or upon an earlier change in control of the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket has been ... for the regeneration and repair of human organs and tissues. ... ambitious expansion plans in Latin America, a commitment made to ... and stem cell therapies. , Bioquark Inc. ... ability to alter the regulatory state of human tissues and ...
(Date:6/2/2015)... June 2, 2015 Meet ARGUS, ... Scanner. Scan & Read People. Analyze emotions and predict ... Concepts, including the very first Responsive-RPG: "The Eye: Genesis". ... , , , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... truly affect your inner feelings - and those of ...
(Date:6/2/2015)... 02, 2015 “Stem Cell Therapy to help ... and it is used often as an adjunct to surgery ... are not yet aware or comfortable enough with the techniques ... most often reserved for the last resort cases - when ... barely lift a paw to get around. It is an ...
(Date:6/2/2015)... 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, ... announced that the Special Committee of the Company,s board of ... ( China ) Limited as its independent financial ... its United States legal counsel and ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company ... its financial results for the fourth quarter and year ... recent operational highlights for calendar year 2009 to date.GeoVax ... quarter ended December 31, 2008, as compared to a ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that it ... North America to its most advanced BiTE antibody candidate, ... conducting a phase 2 clinical trial with blinatumomab for ...
... Production Efficiency and Reliability for New Shire Human Genetic ... HON ) today announced it will help ... development capabilities for creating life-saving medications. Shire Human Genetic ... will use several Honeywell solutions - including Experion(R) ...
Cached Biology Technology:GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 2GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 3GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 4GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 5GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 6GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 7GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 8GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 9GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 10GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 2Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 3Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 4
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
... 2008 Olympic Games, world record times of the men,s 100m ... and technological advances. Imagine if this improvement could be achieved ... Research Institute of Wildlife Ecology in Austria have managed to ... high in polyunsaturated fatty acids. Polyunsaturated fatty acids are ...
... a changing climate depends on the nutritional value and yield ... Australia have found an increase in toxic compounds, a decrease ... under high CO 2 and drought conditions. ... 29 June 2009 at the Society for Experimental Biology Annual ...
Cached Biology News:Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3Mice run faster on high-grade oil 2
...
... Immunoperoxidase Secondary Detection System uses biotin-avidin-HRP complexed ... in the Primary Antibody. The primary antibody ... specimen. Any excess antibody is removed by ... to biotin) is added and will react ...
... Designed specifically for high ... cells. Low toxicity reagent proven ... wide range of cell types. ... than 95% of target gene ...
... Powerful exact mass measurements in ... orthogonal electrospray time-of-flight mass spectrometer (ESI-oa-TOF) ... machine in a format, which fits ... a mass resolution exceeding 10,000 FWHM ...
Biology Products: